Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Only one stop more for Galapagos to market filgotinib

Galapagos initiates the third and final test phase for filgotinib, a candidate drug to treat rheumatoid arthritis, a potential flagship product. T…

POPULAR TAGS

AbbVie as a shareholder of Galapagos

Written by DS on in the category news with the tags , .


About AbbVie as a shareholder of Galapagos, Jan De Kerpel says in De Tijd: “It gives a dual message to investors considering to subscribe to the capital increase. With $ 30 million, AbbVie has already secured 15 percent of the funds. This supports the transaction and means that Abbvie believes in the future of the rheumatism medicine filgotinib. "

AbbVie now owns 2 percent of Galapagos. De Kerpel comments: “That 2 percent is rather symbolic. J & J owns a much bigger part. Look, I do not exclude that Galapagos will be taken over, but currently, AbbVie actually has what it wants. Nobody else can walk away with the license for the rheumatic agent. AbbVie has the first choice. "

Galapagos might have in a few months $ 400 million extra in cash (200 million of the capital increase and Abbvie 200 million of Abbvie): “AbbVie will most likely pay the cost for the further development of filgotinib. Other medications that Galapagos is developing are not yet at the stage where large amounts of money should be invested. Galapagos will probably look to buy external research programs."

Who subscribes to the capital increase, gives the management a blank check."

Read more about: , .

RELATED ARTICLES
Only one stop more for Galapagos to market filgotinib

Galapagos initiates the third and final test phase for filgotinib, a candidate drug to treat rheumatoid arthritis, a potential flagship product. T…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Flanders.bio V-Bio Ventures Janssen KU Leuven Biowin UGent Turnstone XpandInnovation Itera Life Science GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.